Oncotarget

Research Papers:

Elevated CEA is associated with worse survival in recurrent rectal cancer

Won Kyung Cho, Doo Ho Choi _, Hee Chul Park, Won Park, Jeong Il Yu, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Hee Cheol Kim, Yong Beom Cho, Seong Hyeon Yun and Woo Yong Lee

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:105936-105941. https://doi.org/10.18632/oncotarget.22511

Metrics: PDF 568 views  |   HTML 784 views  |   ?  


Abstract

Won Kyung Cho1, Doo Ho Choi1, Hee Chul Park1, Won Park1, Jeong Il Yu1, Young Suk Park2, Joon Oh Park2, Ho Yeong Lim2, Won Ki Kang2, Hee Cheol Kim3, Yong Beom Cho3, Seong Hyeon Yun3 and Woo Yong Lee3

1Department of Radiation Oncology, Seoul, Republic of Korea

2Division of Hematology-Oncology, Department of Medicine, Seoul, Republic of Korea

3Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Correspondence to:

Doo Ho Choi, email: doho.choi@samsung.com

Keywords: CEA; rectal cancer; recurrence; survival

Received: May 18, 2017    Accepted: November 03, 2017    Published: November 18, 2017

ABSTRACT

This study investigated the prognostic impact of serum carcinoembryonic antigen (CEA) level in recurrent rectal cancer. We reviewed 745 patients who developed recurrence after curative treatment for rectal cancer between January 2000 and December 2012. Multivariate analyses for survival revealed that age > 60 years (p = 0.005), r-CEA ≥ 5 ng/ml (p < 0.001), disease free interval (DFI) < 12 months (p < 0.001), and palliative or conservative treatment (p < 0.001) were unfavorable factors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22511